Physicochemical Properties
| Molecular Formula | C16H17CLN2O5S |
| Molecular Weight | 384.834582090378 |
| Exact Mass | 384.054 |
| CAS # | 2112809-98-8 |
| PubChem CID | 134600183 |
| Appearance | White to off-white solid powder |
| LogP | 2.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 25 |
| Complexity | 531 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | ClC1C=CC(=C(C=1)C(NCCC1C=CC(=CC=1)S(NO)(=O)=O)=O)OC |
| InChi Key | KQRQPMUPYDOTCA-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C16H17ClN2O5S/c1-24-15-7-4-12(17)10-14(15)16(20)18-9-8-11-2-5-13(6-3-11)25(22,23)19-21/h2-7,10,19,21H,8-9H2,1H3,(H,18,20) |
| Chemical Name | 5-chloro-N-[2-[4-(hydroxysulfamoyl)phenyl]ethyl]-2-methoxybenzamide |
| Synonyms | JC-171; JC 171; JC171 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In primary macrophages, JC-171 (0-100 μM) dose-dependently inhibits the activation of the NLRP3 inflammasome and the generation of IL-1β [1]. |
| ln Vivo | JC-171 therapy delays the course and lowers the severity of experimental autoimmune encephalomyelitis (EAE) in mice [1]. |
| Cell Assay |
Cell viability assay[1] Cell Types: J774A.1 mouse macrophage Tested Concentrations: 0-100 μM. Incubation Duration: 0.5 hrs (hours) (4.5 hrs (hours) before LPS (1 μg/mL) treatment). Experimental Results: Inhibited the release of IL-1β in J774A.1 cells after LPS/ATP stimulation. |
| Animal Protocol |
Animal/Disease Models: On day 0, mice were immunized subcutaneously (sc) (sc) with 200 μg of myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide emulsified in Freund's complete adjuvant (CFA), followed by injection of 200 ng of pertussis toxin . Doses: 100 mg/kg, 10 mg/kg. Route of Administration: IP on days 0, 1, and 2; every other day thereafter (100 mg/kg). Dosing (10 mg/kg) was started every other day starting when an individual mouse's clinical score reached 1 (flaggy tail). Experimental Results: Compared with vehicle treatment, EAE progression was effectively inhibited. Resulting in a substantial decrease in the frequency of MOG35-55-specific Th17 cells in the spleen and spinal cord of EAE mice. |
| References |
[1]. Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. ACS Chem Neurosci. 2017 Oct 18;8(10):2194-2201. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~649.64 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5986 mL | 12.9928 mL | 25.9855 mL | |
| 5 mM | 0.5197 mL | 2.5986 mL | 5.1971 mL | |
| 10 mM | 0.2599 mL | 1.2993 mL | 2.5986 mL |